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The central nervous system and gastrointestinal tract form the primary targets of
chemotherapy-induced toxicities. Symptoms associated with damage to these regions
have been clinically termed chemotherapy-induced cognitive impairment and mucositis.
Whilst extensive literature outlines the complex etiology of each pathology, to date neither
chemotherapy-induced side-effect has considered the potential impact of one on the
pathogenesis of the other disorder. This is surprising considering the close bidirectional
relationship shared between each organ; the gut-brain axis. There are complex multiple
pathways linking the gut to the brain and vice versa in both normal physiological
function and disease. For instance, psychological and social factors influence motility
and digestive function, symptom perception, and behaviors associated with illness and
pathological outcomes. On the other hand, visceral pain affects central nociception
pathways, mood and behavior. Recent interest highlights the influence of functional
gut disorders, such as inflammatory bowel diseases and irritable bowel syndrome in
the development of central comorbidities. Gut-brain axis dysfunction and microbiota
dysbiosis have served as key portals in understanding the potential mechanisms
associated with these functional gut disorders and their effects on cognition. In this review
we will present the role gut-brain axis dysregulation plays in the chemotherapy setting,
highlighting peripheral-to-central immune signaling mechanisms and their contribution
to neuroimmunological changes associated with chemotherapy exposure. Here, we
hypothesize that dysregulation of the gut-brain axis plays a major role in the intestinal,
psychological and neurological complications following chemotherapy. We pay particular
attention to evidence surrounding microbiota dysbiosis, the role of intestinal permeability,
damage to nerves of the enteric and peripheral nervous systems and vagal and humoral
mediated changes.
Keywords: chemotherapy-induced cognitive impairment, mucositis, chemotherapy-induced gut toxicity, gut-brain
axis, microbiota
INTRODUCTION
The chemotherapy experience is associated with powerful psychological, neurological
and somatic side-effects. Cancer diagnosis and the complications arising from treatment
induce anxiety and depression, fatigue, pain, and cognitive impairments while
patients struggle to maintain hope for recovery and continue normal daily functions,
routines and roles (Kuzeyli Yildirim et al., 2005; Downie et al., 2006; Chan et al.,
2014). Due to the non-selective and systemic nature of most chemotherapy drugs,
Bajic et al. Chemotherapy and Gut-Brain Axis Dysregulation
they also target healthy, rapidly-dividing non-malignant cells.
The regions of the body most susceptible to the unwanted
toxicities of chemotherapy exposure are the gastrointestinal tract
(GIT) and the central nervous system (CNS)—the gut and brain.
Many chemotherapy drugs are small enough to readily cross
the blood-brain barrier and result in molecular, structural and
functional changes within the CNS, manifesting as cognitive
changes in a subset of patients (Wigmore, 2012). Outside of the
CNS, the cells of the GIT are particularly vulnerable to damage
following chemotherapy exposure. In particular, epithelial cells
within the mucosal layer lining the alimentary tract form
prime targets due to chemotherapy drugs targeting proliferating
enterocytes (Sonis, 2004). Although the gut and the brain appear
disparate, they are intimately connected. The complex network
of pathways linking the gut to the brain will be discussed in more
detail below as we present mechanisms by which chemotherapy
results in gut-brain axis dysregulation.
This network has a bidirectional relationship. For instance,
psychological and social factors have the ability to influence
motility and digestive function, symptom perception, behaviors
associated with illness and the pathological outcome (Bhatia and
Tandon, 2005). On the other hand, visceral pain affects central
pain perception and pathways, mood and behavior (Chakiath
et al., 2015). Importantly, systemic and gut immunity is tightly
regulated by the inflammatory reflex and cholinergic anti-
inflammatory pathway (Tracey, 2002; Pavlov and Tracey, 2012).
Integral components of the inflammatory reflex include innate
immune cell activation, release of inflammatory mediators, such
as cytokines, vagal innervation and responses from higher order
brain regions, such as the nucleus tractus solitarius. Vagal
innervation is of particular importance in the chemotherapy
setting as it is pivotal in the transmission of chemo and
mechanosensory information from the gut to the brain (Figure 1;
Goehler et al., 2000; Tracey, 2002). In this sense, proinflammatory
mediators and cytokines, such as interleukin-1 (IL-1) and tumor
necrosis factor (TNF) activate primary afferent nerve fibers
within the vagal sensory ganglia. Vagal ganglia signal several
nuclei of the dorsal vagal complex responsible for the integration
of visceral sensory input and relay information to higher order
brain regions like the hypothalamus, hippocampus and forebrain.
Coordinated autonomic and behavioral responses are initiated
to assist in restoration of homeostasis. Importantly, efferent
vagal motor activity inhibits cytokine synthesis, creating the
inflammatory reflex effect. Humoral anti-inflammatory pathways
can be activated, stimulating the release of adrenocorticotrophin
hormone. Sympathetic outflow can also increase localized
adrenaline and noradrenaline expression and further suppress
inflammation. The activation of these innate components of the
inflammatory reflex, including the vagally-mediated cholinergic
Abbreviations: CICI, Chemotherapy-induced cognitive impairment; ENS, enteric
nervous system; PNS, peripheral nervous system; EGC, enteric glial cells; IBS,
irritable bowel syndrome; IBD, inflammatory bowel diseases; FGIDs, functional
gastrointestinal disorders; BBB, blood-brain barrier; IL-1β, interleukin-1β; IL-
6, interleukin-6; TNF-α, tumour necrosis factor alpha; 5-FU, 5-Fluorouracil;
DSS, dextran sodium sulfphate; CIGT, chemotherapy-induced gut toxicity; TLRs,
toll-like receptors; CIPN, chemotherapy-induced peripheral neuropathy; 5-HT,
serotonin 5-hydroxytryptamine; DCs, dendritic cells.
FIGURE 1 | The inflammatory reflex. (1) The inflamed zone represents tissue
damage, infection and ischemia. (2) Increased expression of inflammatory
mediators and cytokines, such as Il-1β and TNF-α are released by cells in the
inflamed zone. (3) Cytokines activate primary afferent neurons within the vagal
sensory ganglia. (4) Afferent visceral signals are relayed to nuclei in the dorsal
vagal complex (DVC), such as the nucleus tractus solitarius. (5) Visceral
information is further relayed from the DVC to higher order brain regions, such
as the hypothalamus, hippocampus and forebrain. (6) Activation of efferent
vagal motor activity inhibits cytokine synthesis. (7) Hypothalamus activation
stimulates the release of adrenocorticotrophic hormone from the pituitary
gland, initiating a humoral anti-inflammatory pathway. (8) Sympathetic outflow
can increase localized adrenaline and noradrenaline expression further
suppressing inflammation. IL-1β, interleukin-1 beta; TNF-α, tumor necrosis
factor—alpha; DVC, dorsal vagal complex; NTS, nucleus tractus solitarius;
HYP, hypothalamus; HIP, hippocampus; FB, forebrain; ACTH,
adrenocorticotrophic hormone.
efferent output, ultimately results in the regulation of systemic
and localized inflammation, having important implications in
gut immunity (Figure 1). A more comprehensive outline of the
inflammatory reflex has been reviewed elsewhere (Tracey, 2002;
Pavlov and Tracey, 2012).
Additionally, activation of the neuroimmune system via
glial priming and neurogenic inflammation further complicates
immune to brain signaling. Although glial cells are non-
neuronal cell types which can be found in the CNS and
periphery, such as oligodendrocytes and Schwann cells, for the
remainder of this manuscript we specifically refer to microglia
and astrocytes. For an in depth analysis of glial priming and
neuroinflammation several excellent reviews exist (Araque et al.,
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1999; Bains and Oliet, 2007; He and Sun, 2007; Allen and
Barres, 2009; Capuron and Miller, 2011; Parpura et al., 2012;
Dodds et al., 2016). Nonetheless, to illustrate this point in
the context of cancer and chemotherapy, inflammation (either
centrally or locally derived from either the malignancy or
chemotherapy) and the release of proinflammatory cytokines
signals the brain and activates neuroimmunological cells,
glia (Figure 2). Proinflammatory cytokines access the brain
either directly via leaky circumventricular organs or indirectly
via a neural route (e.g., vagal transmission). Microglia and
astrocytes form an integral part of the tri- and tetra-
partite synapses and form a close bidirectional relationship
with neurons; the neuroimmune interface which has wide
implications in central health and disease (Allen and Barres,
2009; Graeber and Streit, 2010; Grace et al., 2014; Dodds
et al., 2016). Reactive glia undergo morphological changes
and overproduce proinflammatory mediators whilst reducing
anti-inflammatory output (O’Callaghan et al., 2008; Agrawal
and Yong, 2011). Ultimately, glial reactivity results in a
neuroinflammatory environment whereby neurotoxicity causes
damage to surrounding tissues and neurons (Eikelenboom
et al., 2006; Bilbo et al., 2012; Laskaris et al., 2015). Centrally
derived neurogenic inflammation and signaling also contributes
to the exacerbation of peripheral inflammatory conditions.
Although glial reactivity may begin with beneficial intentions
by responding to insults (disease, trauma, infection or drug
exposure), glia may remain in a primed state and be sensitized
even after the initial insult has resolved, eliciting an exaggerated
immune responses (Figure 2). Critically, in particular brain
regions primed glia and neuroinflammation influence behaviors
involving cognition and are involved in the pathogenesis of
various neurodegenerative diseases and pathological pain states
(McGeer et al., 1988; Eikelenboom et al., 2006). Due to the
altered immune profile of cancer and chemotherapy patients, it
has been suggested that neuroinflammatory processes may be
contributing to the cognitive deficits often experienced by this
patient group (Myers, 2009; Johnston, 2014). This form of innate
immune (peripheral-to-central) signaling represents a plausible
mechanism meditating chemotherapy-induced gut toxicity and
neurological changes (Figure 2).
Following on from this, it is not surprising that interactions
between the immune system and the brain become dysregulated
under cancer and chemotherapy conditions. Further, recent
evidence has highlighted the impact gut commensal bacteria
has in both central and peripheral development and health
(Feng et al., 2018). Importantly, dysbiosis (microbial
imbalance/maladaptation) and gut-brain axis dysfunction
have been associated with functional gut disorders having
negative effects on cognition (Jones et al., 2006; Frank et al.,
2007). Previously, research has focussed on a single pathological
manifestation of chemotherapy exposure, for example gut
toxicity or regional structural brain changes (Keefe et al., 1997;
Christie et al., 2012). Such studies have failed to consider
the indirect effects of simultaneously occurring treatment-
induced toxicities, which may be contributing to the primary
pathology under investigation. Consequently, we hypothesize
that chemotherapy treatment causes severe and prolonged
FIGURE 2 | Adapted from Dodds et al. (2016). Neuroimmunological
complications arising from cancer and chemotherapy treatment. (1) Cancer
patients undergoing chemotherapy treatment express an altered immune
profile with increases in proinflammatory cytokines. (2) Systemic
proinflammatory cytokines and mediators, such as IL-1 and TNF released
either from the malignancy or treatment-associated toxicities access the brain
directly via leaky circumventricular organs or (3) indirectly via neural
transmission. (4) Systemic or localized proinflammatory mediators and
cytokines signal higher order brain regions and (5) activate microglia and
astrocytes. Reactive glia undergo morphological changes and overproduce
proinflammatory mediators whilst reducing anti-inflammatory output—resulting
in neurotoxicity and neuroinflammation. (6) In particular brain regions primed
glia and neuroinflammation influence behaviors involving cognition and
contribute to various neurodegenerative diseases. (7) Centrally derived
neurogenic inflammation and descending signaling in the spinal cord (8)
contributes to the exacerbation of peripheral inflammatory conditions and
exaggerated pain states. Therefore, peripheral-to-central innate immune
signaling represents a plausible mechanism meditating chemotherapy-induced
gut toxicity and neurological changes. FB, forebrain; HIP, hippocampus; IL-1,
interleukin-1; TNF, tumor necrosis factor.
psychosocial impacts on the survivor. Furthermore, we suggest
that the gut-brain axis is an important mediator of a diverse
range of cognitive and emotional disorders similar to those
experienced by cancer survivors. Here, we will determine
whether chemotherapy affects the gut-brain axis and present
several key stages. Following on from this, we suggest that the
psycho-social side effects of chemotherapy treatment could be
caused by the effects of chemotherapy on the gut-brain axis.
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Following a brief analysis of gut-brain communication,
we will review some key studies linking gut-brain axis
dysregulation to specific psychiatric disorders, highlighting
similarities between these conditions and the chemotherapy
setting. From the bottom-up (GIT to the brain) we will examine
chemotherapy-induced gut and central changes and present
several mechanisms meditating gut-brain axis dysregulation
in the chemotherapy setting; focussing on the microbiome,
intestinal integrity, peripheral neuron and enteric nervous
system (ENS) dysfunction. Finally we will address the role
vagal-, neural-, and humoral-mediated responses may play in
these complex chemotherapy-induced pathological conditions.
Overall, we aim to illustrate the complex role gut-brain axis
dysregulation plays in shaping neurological changes associated
with chemotherapy exposure.
GUT BRAIN CROSSTALK
Since Pavlov’s Nobel Prize-winning discovery on the role
neural innervation plays in gastric secretion—the first functional
evidence connecting the gut and brain—our understanding of
the pathways connecting the CNS and the GIT have significantly
advanced (Keller and William, 1950). The multiple bidirectional
pathways responsible for controlling signaling from the brain
to the gut and vice versa have been extensively reviewed and is
outside the scope of this manuscript (Mayer, 2011; Al Omran and
Aziz, 2014; Carabotti et al., 2015; Furness, 2016). The complexity
of this network is best appreciated in its ability to integrate
information from a variety of systems encompassing the central,
autonomic and enteric nervous systems (including the influence
of the intestinal microbiota), whilst simultaneously considering
neuroendocrine, enteroendocrine and neuroimmune input
(summarized in Figure 3; Carabotti et al., 2015). A brief analysis
of bottom-up and ENS mechanisms is necessary to appreciate
the systems by which the integration of these pathways influence
behavior and impact central comorbidities in disorders of the
gut. We begin this section from the bottom-up; presenting
key pathways, cell types and signaling mechanisms involved in
communication from the gut to the brain. We also illustrate
mechanistic evidence relating to disorders of the gut which
often have a central comorbidity component, such as in
the case of inflammatory bowel diseases (IBD) and irritable
bowel syndrome (IBS). Whilst research covering the central
comorbidities associated with IBD and IBS continues to expand,
the potential mechanisms linking neurological and gut changes
following chemotherapy exposure remains under investigated.
From the Bottom-Up
The GIT elicits a myriad of functions ultimately resulting in
absorption of nutrients and expulsion of noxious chemicals
and pathogens via muscular contractions, cellular, endocrine
and immune mechanisms. Critically, the gut harbors a diverse
microbial community (bacteria, fungi, archaea, viruses, and
protozoa) and has prolific central effects mediating a healthy
host (Feng et al., 2018). Consequently, changes in gut-
microbial composition disrupts physiological homeostasis, often
contributing to central maladaptations (Mu et al., 2016; Dinan
FIGURE 3 | Schematic of a healthy gut-brain axis. The arrows highlight the
bidirectional nature of the gut-brain axis; in a balanced system mechanisms
from the bottom-up (and vice versa) exist in cohesion. In a healthy system, the
gut-brain axis integrates information from many systems; the central nervous
system (CNS), autonomic nervous system (ANS), enteric nervous system
(ENS), neuroendocrine, enteroendochrine, neuroimmune, and
hypothalamic-pituitary axis (HPA). The complex bidirectional communication
pathways and systems shared between the gut and the brain maintain health
and homeostasis in the CNS, GIT, and microbiota. Efferent signals from the
brain involving neuro-endocrine, autonomic and HPA outputs influence motility,
secretion, nutrient delivery and microbial balance in the GIT. Whilst afferent
inputs from the GIT, such as intestinal hormones, cytokines and sensory
perceptions influence neurotransmitter expression, stress, anxiety, mood and
behavior. CNS, central nervous system; ANS, autonomic nervous system;
ENS, enteric nervous system; HPA, hypothalamic-pituitary axis; GIT,
gastrointestinal tract.
and Cryan, 2017). Recent advances in our understanding of
the impact the microbiota has on the gut-brain axis has led
to common use of the term microbiota-gut-brain axis (Rhee
et al., 2009; De Palma et al., 2014). Microbiota-gut-brain axis
communication alters certain aspects of brain development,
function, mood and cognitive processes from both the bottom-
up and top-down (Catanzaro et al., 2014; De Palma et al., 2014;
Mayer et al., 2014; Tillisch, 2014; Carabotti et al., 2015; Barbara
et al., 2016). Evidence specifically related to chemotherapy-
induced microbiota changes will be discussed further below (see
reviews on microbiota-gut-brain axis; Rhee et al., 2009; De Palma
et al., 2014; Mayer et al., 2014; Tillisch, 2014).
The GIT maintains an extensive intrinsic nervous system, the
ENS which is unique in its ability to control certain functions
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of the small and large intestines even when it is disconnected
from the CNS (Furness, 2016). However, the ENS should not
be considered fully autonomous due to the constant top-down
input it receives. The ENS is the largest and most complex
division of the peripheral nervous system (PNS) comprising
400–600 million neurons and an extensive network of enteric
glial cells (EGC) (Furness, 2012). EGCs share similarities with
astrocytes, their CNS counterparts in the mechanisms they
adopt to support enteric neurons, including their morphology,
function and molecular capabilities (Gulbransen and Sharkey,
2009). Importantly, EGCs play key roles in mounting an immune
response, particularly during intestinal inflammation.
Luminal environmental factors, such as mechanical and
chemical changes are signaled from the gut to the brain via
endocrine, immune and neuronal afferent pathways (Mayer,
2011; Furness, 2012; Al Omran and Aziz, 2014; Furness
et al., 2014). Information regarding the level of distension,
concentrations of specific nutrients, electrolytes, pH, and the
presence of danger and immune signals is transmitted from
the gut to the brain via a wide variety of neural and systemic
communication pathways. Visceral changes are detected by a
variety of sensory cell types including enterocytes, intrinsic and
extrinsic primary afferent neurons, immune and enteroendocrine
cells (Carabotti et al., 2015).
Hence, a wide variety of hormones and metabolites
from the gut communicate homeostatic information to
the brain via functional effector cells (enterocytes, smooth
muscle cells, interstitial cells of Cajal, enterochromaffin cells,
intrinsic and extrinsic primary afferent neurons, immune and
enteroendocrine cells) (Carabotti et al., 2015). Examples of
homeostatic information relayed from the functional effector
cells include but are not exclusive to sensory, pH, water
metabolism, chemical, danger and immune signals, etc.). Each
cell type responds to luminal environmental changes and
secretes specific signaling molecules which may include but
are not exclusive to ghrelin, cholecystokinin, glucagon-like
peptide-1, corticotrophin releasing hormone, proteases and
cytokines, etc. (Furness et al., 2014). To further complicate gut-
brain crosstalk, various neurotransmitters commonly produced
centrally are also expressed in the GIT (Furness et al., 2014).
Gut derived neurotransmitters, such as dopamine, serotonin and
neuropeptide Y influence many aspects of central homeostasis,
yet in the gut are responsible for appetite, satiety, hunger, pain
and are implicated in the activation of reward pathways relating
to food and beverage intake (Furness, 2016).
Numerous afferent and efferent pathways connect the gut
and brain, presenting the host with a multitude of platforms for
malfunction, dysregulation and disease, both in the periphery
and centrally. Whilst the basic principles outlining top-down
signaling have been extensively reviewed (Al Omran and Aziz,
2014; Furness et al., 2014; Furness, 2016) and is outside the
scope of this review, it is crucial to acknowledge that these effects
occur simultaneously with those described from the bottom-
up. Importantly, top-down sympathetic and parasympathetic
interactions suppress secretion, motility and GI transit, having
direct effects on immune-, emotion-, mucosa-, and microflora-
related alterations (Lyte et al., 2011; Mayer, 2011). Gut-brain
axis dysfunction has played a pivotal role in our mechanistic
understanding of various gut disorders and their effects on
cognition. Indeed, experimentally induced gut disorders have
critically developed our understanding of the mechanisms
underlying central changes induced by disruptions in gut
homeostasis. Disorders of the gut and chronic inflammation
often result in psychological abnormalities, such as anxiety
and depression (Nyuyki and Pittman, 2015). Additionally,
physiological responses can be induced by stress, for instance
triggering relapse in experimental colitis (Bernstein et al., 2010).
Great interest has recently been paid to the importance
of gut health on mental health and vice versa. This has
become particularly evident in the continual expansion of
anecdotal evidence on the central comorbidities associated with
various gut disorders, particularly in IBS and IBD (Drossman
et al., 1999; Whitehead et al., 2002). Disorders of the gut
are commonly associated with poorer mental health. For
instance, 54–94% of IBS patients actively seeking treatment
also present with emotional, psychological and cognitive
comorbidities (Whitehead et al., 2002) as do chemotherapy
recipients. The literature presented above provides clear evidence
that gut disorders often occur simultaneously with central
comorbidities, aligning with our hypothesis that gut-brain axis
dysregulation may be mediating both chemotherapy-induced
mucositis and neurological changes. Therefore, it is pivotal
that we determine the direct and indirect central consequences
of drug-induced gut disorders, such as chemotherapy-induced
mucositis. Chemotherapy induces a range of peripheral and
central side-effects, significantly reducing quality of life. In the
gut this has been termed chemotherapy-inducedmucositis and in
the CNS, chemotherapy-induced cognitive impairment (CICI).
The current review will now explore whether mucositis and
CICI are linked and whether they exacerbate other symptoms,
such as pain associated with mucositis, or cognitive impairment
which are often experienced simultaneously in the chemotherapy
setting.
CHEMOTHERAPY FROM THE
BOTTOM-UP: THE GUT AND COGNITION
Chemotherapy drugs can be considered paradoxical at the most
basic level. Primarily, they offer recipients’ survivorship as they
target malignant cells in an attempt to rid the host of cancer.
On the other hand, due to their non-selective nature, they also
target healthy cells and induce a range of side-effects reducing
patient quality of life. The organ where their actions are perhaps
often first noticed is the GIT due to its high regenerative capacity.
Mucositis occurs in up to 70% of chemotherapy recipients and
may manifest anywhere along the alimentary tract, termed oral
or intestinal mucositis (Figure 4; Scully et al., 2003). It is one
of the most significant dose-limiting side-effects of intensive
anti-cancer therapy due to the painful nature of the disorder.
Sonis classified the pathogenesis of mucositis into five stages
(Sonis, 2004). Hallmark characteristics of mucositis include villus
atrophy, shallow crypts, inflammation and ulceration. Mucositis
results in a high inflammatory response via the up-regulation
Frontiers in Behavioral Neuroscience | www.frontiersin.org 5 May 2018 | Volume 12 | Article 104
Bajic et al. Chemotherapy and Gut-Brain Axis Dysregulation
FIGURE 4 | Chemotherapy disrupts several stages of the gut-brain axis. The
arrows highlight the bidirectional nature of the gut-brain axis; in an unbalanced
system mechanisms from the bottom-up (and vice versa) are disrupted. We
suggest that chemotherapy-induced gut-brain axis dysregulation plays a major
role in the intestinal, psychological and neurological complications experienced
by many cancer patients. Chemotherapy exposure (1) often results in
molecular and structural changes in the brain (2), e.g., hippocampal changes
as identified in rodent models. Chemotherapy exposure causes cognitive and
behavioral changes (2) to a subset of patients and these findings have been
supported by some experimental models. The altered immune profile of
chemotherapy recipients results in increased circulating pro-inflammatory
cytokines (3) which have been reported to cause cytokine-induced
sickness-like responses (4) which mimic chemotherapy-induced side-effects.
Damage to peripheral nerves resulting in peripheral neuropathies (5) are
experienced by some chemotherapy recipients. Chemotherapy targets the
intestines and its microbial contents causing dysbiosis (6), impairing the nerves
of the myenteric plexus (7), damaging intestinal wall parameters (8), and
resulting in mucositis (9). Serotonin dysregulation under chemotherapy
conditions (10) may play a role in chemotherapy-induced intestinal and
neurological changes. Finally, both humoral and neural/vagal
peripheral-to-central immune signaling pathways (11) may mediate
chemotherapy-induced gut-brain axis dysregulation. Importantly, we
acknowledge that the stress, anxiety and depression associated with cancer
diagnosis and treatment (12) may contribute to both bottom-up and top-down
pathways, having negative effects in the gut and the brain.
and activation of various transcription factors, ultimately causing
elevations in circulating proinflammatory cytokines (Figure 4),
in particular IL-1β and TNF-α (Sonis, 2004). Whilst mucositis
is an acute phenomenon which usually resolves upon cessation
of chemotherapy treatment, clinical symptoms generally begin
5–10 days post-chemotherapy exposure and include significant
pain, abdominal bloating, nausea and vomiting, diarrhea and/or
constipation (Gibson and Keefe, 2006). Although guidelines for
the prevention and treatment of mucositis exist, they fail to
include effective treatment options (Gibson et al., 2013). Novel
complementary treatment approaches are showing positive
results utilizing naturally sourced products, such as Emu Oil
and Rhubarb extract (Mashtoub et al., 2013; Bajic et al., 2016a).
Although these treatment strategies show promise, to date they
are still in the pre-clinical stages.
Our understanding of the central consequences of drug-
induced gut disorders, such as mucositis remains elusive,
yet evidence on CICI is expanding as various mechanisms
underlying its pathogenesis are becoming clearer. CICI occurs
in 15–45% of patients undergoing anti-cancer therapy (Figure 4;
Vardy and Tannock, 2007). Subjective (self-report) report rates
are considerably higher than objective measures with some
studies reporting 95% of patients experiencing changes in
cognitive performance (Downie et al., 2006). Subjective measures
are nonetheless important as they identify the impact of cognitive
impairment and the strain it places on patients’ lives and daily
functioning (Shilling and Jenkins, 2007). The breast cancer
population forms the majority of the CICI literature as they offer
researchers completion of extensive retrospective studies due to
their typically good prognosis (Ahles et al., 2010). Regardless,
CICI has been investigated in a range of other cancer types
including myeloma and testicular cancer (Schagen et al., 2008;
Potrata et al., 2010).
The cognitive domains most commonly reported in CICI are
executive functioning, attention and concentration, processing
speed, reaction time and motor speed and dexterity (Asher,
2011). Perceived cognitive impairment affects various facets
of the patient’s life, including relationships, employment, self-
esteem/worth, finances and independence. The CICI experience
leaves patients feeling distressed, anxious, frustrated, irritable,
depressed and embarrassed, often reducing confidence (Mitchell,
2007; Von Ah et al., 2013). Current estimates on the duration
of CICI are varied with some studies identifying deficits up
to 20 years post-chemotherapy cessation, yet most indicate
improvements up to 12 months later (Collins et al., 2009;
Koppelmans et al., 2012). Neuroimaging studies have confirmed
molecular and structural changes in the gray matter of the
frontal and temporal lobes and the cerebellum of breast cancer
patients following chemotherapy exposure (Silverman et al.,
2007; McDonald et al., 2010). Additionally, chemotherapy
induces white matter tract changes and the reorganization of
global brain networks, which have undoubtable associative if not
causal impacts on cognitive performance (Abraham et al., 2008;
Bruno et al., 2012).
Animal studies have begun to unravel various mechanisms
underlying the pathogenesis of CICI and involve structural and
behavioral changes. Hippocampal and frontal cortical alterations
have correlated with behavioral memory changes in various
rodent models (Figure 4; Yang et al., 2010, 2012; Wigmore,
2012). Neurogenesis occurs in the dentate gyrus and cellular
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proliferation is critical in hippocampal circuit plasticity and
memory consolidation (Deng et al., 2010; Ming and Song, 2011).
CICI models have reported on the vulnerability of stem cells
to proliferate in the dentate gyrus irrespective of chemotherapy
drug class (Briones and Woods, 2011; El Beltagy et al., 2012).
Considering the pivotal role neural stem cells in this region have
to divide into new neurons or astrocytes, disruptions in this
process present as a direct mechanismwhichmay be contributing
to CICI. More recently, neuroimmunological manifestations,
such as glial dysregulation and neuroinflammation, have been
reported to contribute to CICI (Briones and Woods, 2013; Bajic
et al., 2016b).
Currently, effective prevention strategies or treatment
approaches for CICI remain undetermined although two
evidence-based guidelines are available to assist oncologists
in addressing cognitive deficits (Network, 2015). Other
interventions for CICI are broadly categorized into cognitive
training, compensatory strategies, pharmacological, and
complementary and integrative medicines (Vance et al., 2017).
Recently, Toll-like receptors (TLRs) have been suggested as a
common component in the pathology of neuropathy/pain and
chemotherapy-induced gut toxicity, presenting a novel andmuch
needed therapeutic approach in the treatment of chemotherapy-
induced toxicities (Wardill et al., 2015). TLRs have profound
homeostatic effects, tightly regulating innate immune and
gut functions, modulating pain behaviors (Akira and Takeda,
2004; Rakoff-Nahoum et al., 2004; Doyle and O’Neill, 2006;
Hutchinson et al., 2010, 2012; Gibson et al., 2016). Wardill
et al. (2015) hypothesized that TLR-4 mediates glial activation
and neuropathy driven by the molecular signals released from
chemotherapy-induced gut toxicity. Primary studies have
indicated that an altered TLR expression profile may contribute
to chemotherapy-induced pain and diarrhea (Gibson et al., 2016).
This study importantly highlights the need for further research
examining both peripheral and central toxicities associated with
chemotherapy treatment. Interestingly, the selective serotonin
reuptake inhibitor, fluoxetine, has shown promising results in
a rat model of CICI. Fluoxetine co-administration with the
chemotherapy drug improved cognitive performance in rats
assessed by object location recognition (Lyons et al., 2012).
Whilst cellular proliferation in the dentate gyrus significantly
reduced in the chemotherapy group, co-administration with
fluoxetine reversed this reduction. Regardless of the evidence
presented here indicating CNS changes following chemotherapy
exposure, it is important to note that some studies have reported
no structural or cognitive changes (Fremouw et al., 2012; Wilson
and Weber, 2013). Various cytotoxic insults have revealed no
morphological changes to neurons located in the CNS (Ginos
et al., 1987; Gangloff et al., 2005). These negative findings
could result from a range of factors, including differences
in species, drug, dose, type of administration and cognitive
parameters examined; but importantly, suggests that more
complex mechanisms are likely to play a role in CICI.
Whilst the direct mechanisms presented here reflect the
complex etiology of CICI, they fail to acknowledge the influence
other simultaneously occurring side-effects may be having on
CICI symptoms. Many of the CICI models described above
utilized chemotherapy drugs that are also often used to examine
mucositis, for example 5-Fluorouracil (5-FU), methotrexate and
oxaliplatin. Although mucositis would have most likely been
present in these models, the gut tissue would not have been
examined and thus, the potential for indirect mechanisms
relating to gut-brain axis dysregulation would have been ignored.
In doing so, we may be missing critical mechanisms contributing
to or exacerbating CICI pathogenesis. In order to explore
this theory, we will now consider the influence chemotherapy
exposure has on the gut-brain axis, opening novel hypotheses
surrounding how mucositis may contribute to the etiology of
CICI.
CHEMOTHERAPY INTERRUPTS SEVERAL
STAGES OF THE GUT-BRAIN AXIS
As presented above, the two organs most vulnerable to the
toxicities of chemotherapy treatment are the gut and the brain.
Therefore, it is plausible that several stages of the gut-brain
axis may become dysregulated in the chemotherapy setting
(Figure 4). Here, we propose that chemotherapy exposure
influences the gut-brain axis via several mechanisms which
include: altering intestinal microbiota composition and function;
upsetting the balance of “beneficial” and “detrimental” bacteria
in the lumen, deleteriously affecting the gut lining, impairing
the ENS and activating neuroimmune and pain signaling
pathways (Figure 4). The interaction of the gut-brain axis and
the neuropsychological comorbidities associated with specific
gut disorders have been extensively reviewed, for example
depression/cognitive deficits and IBS/IBD (Whitehead et al.,
2002; Attree et al., 2003; Filipovic and Filipovic, 2014; Fond
et al., 2014; Padhy et al., 2015). However, this angle of research
is yet to be reviewed in the context of chemotherapy exposure
and cognitive impairment. Research in this area will continue to
develop as we begin to appreciate that chemotherapy-induced
side-effects involving the gut-brain axis may continue to linger
for some time after treatment cessation, placing significant strain
on health care and importantly, patient quality of life.
The Microbiome
It has been estimated that our gut contains 100-fold more
genes than the human genome and approximately 1,000 bacterial
species (Ley et al., 2006; Qin et al., 2010). Our gut microbiome
coevolves with us (Ley et al., 2008) and changes may be either
beneficial or detrimental to human health. In healthy individuals,
the gut microbiota is responsible for a number of health benefits,
such as pathogen protection, nutrition, host metabolism and
immune modulation (O’Hara and Shanahan, 2006). Although a
core microbial population has been established in individuals,
changes can be caused by many factors including age, diet,
antibiotic and analgesic use and environmental factors (Jalanka-
Tuovinen et al., 2011). The microbiome facilitates intestinal
homeostasis and more specifically, has the capacity to influence
inflammation and immunity, both at the local (mucosal) and
systemic levels (Clemente et al., 2012). Commensal bacteria
play important roles in anti-viral immunity, regulating systemic
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immune activation (Abt et al., 2012). Signals released by
commensal bacteria assist in immune development and thereby,
have important implications for infectious and inflammatory
disease susceptibility (Ichinohe et al., 2011; Abt et al., 2012),
such as in the case of chemotherapy-induced mucositis.
Consequently, dysbiosis can heavily influence pathological
intestinal conditions with an inflammatory component, for
example in experimentally-induced IBD (García-Lafuente et al.,
1997; Dalal and Chang, 2014; Touchefeu et al., 2014; Håkansson
et al., 2015). Critically, IBD patients reported microbial
composition changes with major shifts in genomic landscape
and functional outcomes (Morgan et al., 2012). Undoubtedly, the
implications of such IBD studies have heavily impacted oncology,
raising many questions specifically relating to the intestinal
microbiota, immune, malignancy and anti-cancer treatment
interactions.
Whilst Sonis’ five-phase model of mucositis (Sonis, 2004)
lacked any potential influence on the microbiota, unequivocal
research has indeed confirmed that intestinal inflammation
modulates microbiome composition and function (Morgan et al.,
2012; Touchefeu et al., 2014). As intestinal inflammation is
a common characteristic of mucositis, it makes sense that
chemotherapy induces functional and compositional changes
to the microbiome. It has been suggested that mucositis
development is influenced by commensal bacteria in multiple
pathways involving inflammation and oxidative stress, intestinal
permeability (discussed below), mucus layer composition,
epithelial repair mechanisms and via the release of immune
effector molecules (van Vliet et al., 2010). Indeed, research has
begun to unravel the complexities surrounding the interactions
between the host and the intestinal microbiota following
chemotherapy exposure and consequently, several excellent
reviews exist (van Vliet et al., 2010; Touchefeu et al., 2014;
Dzutsev et al., 2015; Vanhoecke et al., 2015; Zitvogel et al.,
2015). Commonly used chemotherapy drugs, such as 5-FU and
irinotecan report drastic shifts in intestinal microflora, from
commensal bacteria which maintain a symbiotic relationship
with the host, to elevated levels of Escherichia spp., Clostridium
spp., and Enterococcus spp. which can be associated with
several pathologies involving inflammation and infection (Von
Bültzingslöwen et al., 2003; Stringer et al., 2007, 2009; Lin et al.,
2012;Table 1). Several clinical studies have supported pre-clinical
findings describing alterations in fecal microbial composition
following chemotherapy treatment. Literature reveals a general
decrease in the overall diversity of bacteria in the microbiota
of cancer patients undergoing anti-cancer treatment when
compared to healthy individuals, irrespective of cancer type or
chemotherapy regime (Manichanh et al., 2008; Zwielehner et al.,
2011; Montassier et al., 2014; see Table 1).
In addition to the direct effects microorganisms and their
enzymes have on cancer initiation and progression (Sears and
Garrett, 2014; Gagnière et al., 2016), the microbiota also modifies
drug absorption and metabolism via gene expression changes
(Carmody and Turnbaugh, 2014; Wilson and Nicholson, 2017).
This has become a pivotal research angle in oncology as
chemotherapy-microbiota-immune interactions have identified
microbial-mediated innate and adaptive immune responses and
their effect on the efficacy of cancer immunotherapy and
chemotherapy drugs (Iida et al., 2013; Viaud et al., 2013; Sivan
et al., 2015; Vétizou et al., 2015). Two crucial studies in Science
Iida et al. (2013); Viaud et al. (2013) reported that microbiota
disruption by antibiotic treatment impaired chemotherapy drug
efficacy on tumors, utilizing cyclophosphamide and oxaliplatin.
More recent studies have illustrated the important role certain
microbial strains (Bifidobacterium) play in anti-tumor immunity
(Sivan et al., 2015; Vétizou et al., 2015). Although these
studies were performed in mice, their findings indicate the
potential risks associated with the use of antibiotics during
chemotherapy treatment. The growing field of microbiome
research has raised a lot of questions and comments on
the complex interplay and interwoven relationships between
microbes and cancer, including anti-cancer treatments (Pennisi,
2013; Bordon, 2014; Greenhill, 2014; Lokody, 2014; Mukaida,
2014). Further, some of the above studies (Sivan et al., 2015;
Vétizou et al., 2015) have implications for microbial therapy
in cancer immunotherapy. As our understanding of these
interactions continues to progress, new knowledge in this
area will open up possibilities of novel paradigm shifts in
treatment approaches which may improve anticancer efficacy
and even prevent toxicity. The studies presented in this section
suggest a role for chemotherapy-induced dysbiosis in intestinal
disease pathogenesis and chemotherapy-induced gut-brain axis
dysregulation (Figure 4). As mentioned, commensal bacteria
are critical in regulating intestinal homeostasis and more
specifically, intestinal integrity. In fact, the effects commensal
bacteria have on intestinal integrity and vice versa, go hand-in-
hand. Accordingly, the reciprocal relationship shared between
commensal bacteria and the intestinal wall will be presented
together in the following section. Chemotherapy compromises
intestinal integrity and leads to profound effects on the gut
lining, eventually leading to a dysbiotic microbial community




The even comprehensively described pathogenesis of mucositis
(Sonis, 2004) is unable to fully encapsulate the mechanisms
underlying the pathogenesis of chemotherapy-induced gut
damage. Although it covers many essential aspects of the
pathological processes underlying mucositis, such as epithelial
barrier damage. More recently, some research groups have re-
defined gut damage caused by chemotherapy as chemotherapy-
induced gut toxicity (CIGT). The proposed term includes
additional pathological manifestations caused by chemotherapy
treatment, such as abnormalities in tight junctions, immune
dysfunction and microbiota influences (Montassier et al., 2014;
Touchefeu et al., 2014; Wardill et al., 2014).
Nonetheless, the epithelial barrier lining of the GIT is
fundamental in ensuring the maintenance of intestinal integrity.
As well as forming a mechanical barrier to separate the
inside of the body from the outside world, it is heavily
involved in the communication shared between the body
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TABLE 1 | Summary of key papers highlighting chemotherapy-microbiota-immune interactions.
Study Subjects Treatment Commentary
Lin et al., 2012 Tumor bearing rats Irinotecan alone Irinotecan/5-FU Increased abundance clostridial clusters I, XI, and
Enterobacteriaceae.
Von Bültzingslöwen et al., 2003 Rats 5-FU Increased facultative and anaerobic bacteria
from the oral cavity.
Increased facultative anaerobes in large intestine.
Proportion of facultative gram-negative rods increased in
both oral cavity and intestine.
Stringer et al., 2009 Rats Irinotecan Increased jejunal samples of Escherichia spp.,
Clostridium spp., Staphylococcus spp.
Increased colonic samples of Escherichia spp.,
Clostridium spp., Enterococcus spp., Serratia spp.,
Staphylococcus spp.
No changes in fecal flora except E. coli.
Stringer et al., 2007 Rats Irinotecan Extensive changes were evident in stomach, jejunum,
colon and feces.
Most significant changes were in colon, indicating a
relationship between colon bacteria modification and
diarrhea incidence.




Steep reduction in alpha diversity during chemotherapy.
Decreases in Firmicutes bacteria and Bifidobacterium
whilst
Bacteriodes and Esterichia were increased
Manichanh et al., 2008 Patients with abdominal
tumors
Pelvic radiotherapy Faecal samples reported significant microbiota profile
changes in patients with post-radiotherapy diarrhea. Not
all patients reported diarrhea. Importantly, this study
suggests initial microbial colonization may be linked to
susceptibility or protection against diarrhea following
radiotherapy treatment.




Chemotherapy decreased Clostridium cluster IV and
XIVa. C. difficile was present in three out of seventeen
patients and was accompanied by a decrease in the
genera Bifidobacterium, Lactobacillus, Veillonella and
Faecalibacterium prausnitzii. Enterococcus faecium
increased following chemotherapy.
Iida et al., 2013 Tumor bearing mice Oxaliplatin and cisplatin Chemotherapy-induced dysbiosis impairs response to
immunotherapy and chemotherapy.
Viaud et al., 2013 Tumor bearing mice Cyclophosphamide Jejunal and fecal samples reported dysbiosis and
induces translocation of specific Gram-positive bacteria
to secondary lymphoid organs whereby they stimulate
subsets of T cells. These results suggest that the gut
microbiota may affect anticancer immune response.
Sivan et al., 2015 Tumor bearing mice Co-housing, fecal transfer,




Changes to anti-tumor immunity were eliminated by
co-housing and fecal transfer. Oral Bifidobacterium
administration improved tumor control to same degree
as PDL-1 therapy; combination treatment nearly
abolished tumor outgrowth.




regulates T cell activation and
improves survivability of
metastatic melanoma patients.
CTLA-4 blockade is influenced by the microbiota.
Changes in B. fragilis and/or B. thetaiotaomicron and
Burkholderiales affects immune response facilitating
tumor control in mice and patients.
and the intestinal contents (Powell, 1981). Tight junctions
are intertwined throughout the epithelial barrier and regulate
diffusion of solutes according to strict size and charge limitations
(Balda and Matter, 2016). Chemotherapy exposure increases
intestinal permeability and the most widely studied mechanisms
to date have included apoptosis of intestinal crypts and villous
atrophy (Keefe et al., 2000; Carneiro-Filho et al., 2004). Early
clinical studies assessing the severity of intestinal damage in high
dose regimes reported abnormalities in intestinal permeability
and defects in tight-junction integrity (Figure 4; Keefe et al.,
1997). Convincing rodent evidence has implicated mucosal
barrier injury and tight junction deficits with gut toxicity
induced by various chemotherapy drugs, including irinotecan
and methotrexate (Beutheu Youmba et al., 2012; Wardill et al.,
2014). However, it should be noted that rodent model application
in gut immunity andmicrobiome research has serious limitations
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and pitfalls due to compositional microbiota differences between
species. Whilst the rodent microbiome shares some common
features with human commensal bacteria, unique commensals
in rodents have differential effects in immune responses and
disease pathogenesis (Nguyen et al., 2015). Consequently, animal
models of inflammation are different to human models of
inflammation in terms of microbial colonization, morphology
of lesions and clinical manifestations. Nonetheless, research in
experimental models continues to provide critical insight into
complex interactions between the host, microbiota and immune
responses. More recently, it has been becoming more evident
the impact intestinal integrity has on the microbiota and vice
versa, especially under chemotherapy conditions. The health and
stability of the intestinal wall influences the microbiota and vice
versa.
Commensal bacteria in the microbiota have a protective
effect on intestinal integrity, interacting with TLR and Nuclear
Factor kappa B pathways, ensuring the development of an
innate immune response (Doyle and O’Neill, 2006). These
components of innate immunity in the gut and the activation
of these pathways are pivotal in maintaining barrier function,
promoting mucosal repair and protecting the gut against injury
(Rakoff-Nahoum et al., 2004; Cario, 2008). Chemotherapy
exposure alters commensal microbial composition in the
microbiota, thus negatively affecting barrier function, repair
pathways and compromising intestinal integrity (Stringer
et al., 2009). Accordingly, further investigations are required
to fully appreciate the role chemotherapy-induced intestinal
permeability changes play in gut-brain axis dysregulation. As
intestinal integrity becomes compromised under chemotherapy
conditions, it is not surprising that nerves of themyenteric plexus
and peripheral nerve endings become damaged as these neural
components also reside outside of the blood-brain barrier (BBB)
as will be discussed below.
Chemotherapy Results in Peripheral and
Enteric Neuropathy
The PNS is particularly vulnerable to the cytotoxic nature of
different chemotherapy drug classes, including platinum analogs,
antitubulins, proteasome inhibitors, immunomodulatory
agents and some newer biologics, such as brentuximab
(Cavaletti and Marmiroli, 2015). Chemotherapy-induced
peripheral neuropathy (CIPN) is experienced by 30–40%
of chemotherapy recipients and is often responsible for
early cessation of treatment, decreasing chemotherapeutic
efficacy and causing higher relapse (Wang et al., 2012; Areti
et al., 2014). Typically, sensorimotor symptoms are more
common than motor involvement, presenting in a bilateral
“glove-and-stocking” distribution in the hands and feet to
include paraesthesia, numbness, burning pain, allodynia and
hyperalgesia (Windebank and Grisold, 2008). However, the
development of motor and autonomic neuropathic symptoms
may also occur, such as sensory ataxia, pain, weakness of
distal muscles, reduced deep tendon reflexes and severe
numbness that can severely affect the patient’s ability to
function and their quality of life (Park et al., 2013). Often
symptoms fail to improve after cessation of treatment, referred
to as a “coasting” phenomenon (Windebank and Grisold,
2008).
The pathogenesis of CIPN is primarily related to axonopathy
and neuronopathy in which dorsal root ganglia (DRG) are
involved. Peripheral nerves and their ganglia are particularly
susceptible to chemotherapy-induced damage due to their
location as they lack the protective defenses associated with the
BBB (Furness et al., 2014). For example, chemotherapy interrupts
the cell cycle, inducing structural and functional changes in
DRGwhich partly explain the development of sensory symptoms
in CIPN (Gill and Windebank, 1998; Cavaletti et al., 2000).
Many pathophysiological mechanisms mediating chemotherapy-
induced peripheral nerve damage have been identified. Some
examples include, but are not exclusive to dysregulated
axonal transport and trophic factor support via microtubule
structural changes (Theiss and Meller, 2000), mitochondrial
stress (McDonald and Windebank, 2002; Chen et al., 2007) and
reduced blood supply to nerves (Theiss andMeller, 2000; Isoardo
et al., 2004). Further changes contributing to CIPN pathogenesis
include dysregulated ion channels, neurotransmitter release and
receptor sensitivity (Descoeur et al., 2011; Mihara et al., 2011;
Tatsushima et al., 2011). The evidence presented here clearly
describes mechanisms by which the PNS is damaged following
chemotherapy exposure, forming an important element of the
proposed central hypothesis (Figure 4).
In addition to peripheral neuropathies, neurons residing
within the ENS are also susceptible to the deleterious effects
of various chemotherapy drugs, including cisplatin, oxaliplatin
and more recently, 5-FU (Vera et al., 2011; Wafai et al.,
2013; McQuade et al., 2016). Systemic administration of these
chemotherapy drugs induces structural and functional changes
to myenteric neurons (Figure 4), consequently resulting in
downstream negative effects on GI motility. Interestingly, acute
exposure of 5-FU increases intestinal transit whilst prolonged
treatment decreases transit time (McQuade et al., 2016). These
findings outline the complex nature chemotherapy drugs have
on enteric neurons and altered motility patterns. Here, we
highlight that chemotherapy results in damage to neurons
and ganglia residing outside of the BBB, exerting functional
maladaptations in both the PNS and ENS. So far we have
described several mechanisms relating to chemotherapy-induced
gut-brain axis dysregulation, yet we have not identified how
immune signals from the intestinal cavity may communicate
to the brain and potentially contribute to the pathogenesis
of CICI. In the following section we present peripheral-to-
central immune pathways as being critical in the transmission




Induced Gut-Brain Axis Dysregulation
Historically there has been controversy surrounding the theory
that a communication system existed between the immune
system and the CNS (Dantzer and Kelley, 2007). Traditionally
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it was assumed that proinflammatory cytokines were unable to
pass through the BBB due to their size. However, the humoral
route explained that cytokines expressed in the periphery could
in fact cross the BBB at leaky circumventricular organs through
fenestrated capillaries. At these sites blood-borne cytokines act
on parenchymal astrocytes that express secondary mediators,
such as nitric oxide and prostaglandins which freely diffuse
to nearby brain regions, such as the hypothalamus to mediate
the effects of pyrogenic and corticotropic cytokines (Katsuura
et al., 1990). Whilst this hypothesis leads toward the existence
of a communication system between the immune system and
the CNS, it was unable to fully account for other contributing
pathways that may be mediating physiological responses.
Consequently, it is now widely accepted that peripheral cytokines
signal the brain and in turn, this triggers sickness behavior
responses (Dantzer, 2004).
Central or peripheral immune challenges trigger a range
of physiological, behavioral and motivational changes to assist
the host in healing (Figures 2, 4). Non-specific symptoms
which accompany sickness behaviors include, but are not
exclusive to fever, depressed activity, a loss of interest in regular
activities (appetite, sexual, cleaning, hygiene), weakness, malaise,
listlessness and cognitive changes (Dantzer and Kelley, 2007).
As demonstrated by Dantzer and Kelley (Dantzer and Kelley,
2007), the last two decades of research on this phenomenon
have confirmed that local or systemic proinflammatory cytokines
expressed at physiological levels, during both acute and chronic
inflammatory responses, serve as true communication molecules
between the immune system and brain. For example, direct
administration of IL-1β or TNF-α to the lateral ventricle
decreased social exploration and feeding behavior in rats (Kent
et al., 1992). In the chemotherapy setting, this phenomenon may
be related to either the systemic nature of the drugs themselves
or localized inflammatory responses occurring as a result of the
toxicities associated with their use, such as in the case ofmucositis
(see Figure 2).
Interestingly, whilst IL-1β and TNF-α are key
proinflammatory cytokines instigating sickness behavior
responses, they also play a pivotal role in the pathogenesis
of mucositis. Since both proinflammatory cytokines play an
important role in the pathogenesis of mucositis and sickness
behaviors which involve cognitive deficits, it is plausible that
these cytokines and the pathways mediating their activation
may present as key mechanisms underlying the central
hypothesis in this review (Figure 4). Various animal models
have identified that sickness behavior responses may be
induced by a range of clinical conditions, such as systemic or
central administration of lipopolysaccharide (active fragment
of gram negative bacteria) or recombinant proinflammatory
cytokines (Tomas et al., 1984; Goehler et al., 1999; Dantzer
and Kelley, 2007). Furthermore, many symptoms associated
with cytokine-induced sickness responses mimic the cluster
of chemotherapy-induced side-effects, including fatigue,
depression, reduced appetite, heightened sensitivity to pain and
cognitive impairment (Figure 4). As previously mentioned, up
to 70% of chemotherapy recipients experience mucositis (Scully
et al., 2003) and an altered immune profile due to the systemic
nature of anti-cancer treatments, yet whether these side-effects
may be contributing to CICI remains elusive. Accordingly, we
present pathways which may be enabling the communication
of peripheral immune signals to the brain, more specifically
defining how mucositis-driven inflammation may signal the
brain via vagal- and neural-mediatedmechanisms and contribute
to the pathogenesis of CICI.
Information from proinflammatory cytokines and mediators
expressed under chemotherapy-induced mucositis conditions
may signal the brain via a vagal communication pathway
(Figure 4). Dendritic cells (DCs) are a specialized subset of
immune cells located within the vagus nerve and surrounding
paraganglia (Goehler et al., 1999). The signals (proinflammatory
cytokines, chemokines and mediators) expressed by DCs
are capable of communicating to the brain (Banchereau
and Steinman, 1998; Reis e Sousa et al., 1999). Vagal
immunosensation requires primary afferent neuron activation as
the initial interface triggering the brain. Following chemotherapy
exposure, proinflammatory cytokines and mediators, such as
those from the IL-1 family arise from mucositis-induced
inflammation. IL-1 binds to receptors on the paraganglia
surrounding vagal afferents and release neurotransmitters onto
the vagus, consequently activating vagal fibers. A vagal-mediated
neural signal is then carried to the nucleus tractus solitarius
which projects the message to higher order brain regions,
such as the hypothalamus and hippocampus, whereby, IL-
1 production is increased and other neural cascading events
are initiated to produce sickness behavior responses (Dantzer
and Kelley, 2007; Wardill et al., 2015). Whilst this evidence
clearly demonstrates the role that vagal afferent nerves play in
peripheral-to-central transmission of immune messages from
the abdominal cavity, to date these pathways have not been
examined under chemotherapy conditions and are therefore
presented as potential mechanisms contributing to gut-brain axis
dysregulation.
DCs play a role in immunomodulation and neuroimmune
regulation, crucially bridging innate and immune adaptive
processes. Importantly, DCs express pattern recognition
receptors for a range of chemicals (e.g., TLRs), chemokines,
microorganisms and neurotransmitters, such as serotonin
(Banchereau and Steinman, 1998; Reis e Sousa et al., 1999).
Damage to surroundings GIT tissues and increased levels of
proinflammatory mediators, such as cytokines and chemokines
induce maturation of DCs (Ricart et al., 2011). Matured DCs
migrate to secondary lymphoid organs to initiate a localized
immune response via interacting with naïve T cells (Banchereau
and Steinman, 1998). Recent data implies an emerging role for
DC-expressed serotonin and receptor activation in regulating
innate and immune responses associated with gut inflammatory
conditions (Holst et al., 2015; Szabo et al., 2018). Mechanisms
underlying DC-mediated serotonin and receptor-sub types
affect various levels of localized inflammation, even having
anti-inflammatory effects preventing excess inflammation and
tissue damage (Szabo et al., 2018). These findings coupled with
the aforementioned positive cognitive effects of fluoxetine in a rat
model of CICI (Lyons et al., 2012), serotonin presents as a new
therapeutic approach for inflammatory disorders, having effects
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in both the gut and the brain. Accordingly, serotonin is presented
as an underestimated contributing factor potentially implicated
in chemotherapy mediated gut-brain axis dysregulation (see
Wigmore, 2012 ).
CONCLUSION
From the bottom-up, the gut and the brain are the two
primary organs most susceptible to toxicity associated with the
non-selective nature of chemotherapy drugs. As chemotherapy
exposure induces cognitive decline and mucositis in a subset
of recipients, it makes sense that several stages of the gut-
brain axis are prone to negative effects in this setting. The
gut-brain axis is largely responsible for the maintenance of
homeostasis and achieves this delicate balance by integrating
a vast array of signals and information from many systems,
as described above and shown in the figures. In this regard,
upsetting the balance of any stage in the gut-brain axis following
chemotherapy treatment has the potential to exacerbate side-
effects, such as in the case of mucositis and CICI. The findings
from our review support ourmain hypotheses that chemotherapy
treatment causes severe and prolonged psychosocial impacts
on the survivor. Secondly, the gut-brain axis is an important
mediator of a diverse range of cognitive and emotional disorders
similar to those experienced by cancer survivors. Evidently,
chemotherapy affects the gut-brain axis at several key stages
which are outlined above. Collectively, we conclude that the
psycho-social side-effects of chemotherapy treatment may be
caused by the effects of chemotherapy on the gut-brain axis.
Apart from chemotherapy treatments crossing the BBB
and directly causing damage to specific regions, peripheral
inflammatory responses from either the malignancy or systemic
treatment also indirectly cause cellular changes in the spinal
cord. We recently demonstrated glial dysregulation in the
thoracic region of rats with 5-FU-induced intestinal mucositis
indicating an indirect regional-specific neuroimmune response
to CIGT (Bajic et al., 2015). Our data provides evidence that
experimentally-induced jejunal toxicity indirectly downregulates
thoracic astrocytic expression. In addition to this recent
finding, the evidence presented here suggests a role for
chemotherapy-induced dysbiosis in intestinal inflammation.
This further complicates intestinal inflammation and ulceration
induced by chemotherapy exposure which may potentially
influence CICI. Neurons in both the ENS and the PNS are also
vulnerable to the cytotoxic nature of chemotherapy treatments.
The implications of co-administration of pharmacological
interventions (e.g., fluoxetine) with chemotherapy drugs
remains undetermined, although preliminary studies showing
improvements in cognitive performance warrants further
investigation. In view of the aforementioned data, we
conclude that several stages of the gut-brain axis become
dysregulated following chemotherapy exposure and may
be implicated in the pathogenesis of CICI. Harnessing our
understanding of the role gut-brain axis dysregulation plays in
modulating brain function may offer clues for more targeted
therapeutic strategies to prevent CICI and warrants further
investigation.
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